HPLC-based DNA and RNA Purification Service
Description of HPLC
With the development of biotechnology, certain important biological preparations and pharmaceuticals, which are mainly composed of biological macromolecules, often fail to meet the required purification requirements by using traditional separation and purification techniques (ultrafiltration, precipitation, extraction, and centrifugation, etc.). Therefore, the focus on separation and purification techniques has been shifted to chromatography. In recent years, high-performance liquid chromatography (HPLC) has been at the forefront of contemporary high-performance separation and purification techniques. HPLC is a very important separation and purification technique in organic chemistry and biochemistry. It is divided into normal-phase chromatography and reversed-phase chromatography. Normal-phase chromatography and reversed-phase chromatography can be further divided into adsorption chromatography and polar chemical bonding chromatography. Since polar compounds are more easily retained by polar stationary phases, normal-phase chromatography is generally more suitable for the separation of polar compounds, and reversed-phase chromatography is generally suitable for the separation of non-polar and weakly polar compounds.
Fig.1 DNA and RNA structure. (Wikipedia)
Key Technologies
The key technology of this service is HPLC, which utilizes three specialized separation modes: reversed-phase HPLC (separates by hydrophobicity), ion-exchange HPLC (separates by charge), and ion-paired reversed-phase HPLC (enhances resolution for charged molecules), employing various column matrices like silica gel, polymer, and Al2O3 to achieve high-purity DNA and RNA purification.
Sugar-Shielded Precision: DNA & RNA, HPLC-Refined.
DNA and RNA are two biomolecules that require high purity for various applications. At CD BioGlyco, we offer HPLC technology for the separation and purification of DNA and RNA to produce higher-purity DNA and RNA. The HPLC process utilizes the "adsorption-elution" principle, and we offer different separation modes for different substances, as shown in Table 1.
Table 1 Sample selection for separation.
| Molecular mass | Solubility / Specificities | Chromatography type | |
| Less than 2000 | Soluble in organic solvents | Soluble in heptane | Silica; Normal-phase chromatography |
| Bonding; Normal-phase chromatography | |||
| Soluble in CH3OH / CH3CN / H2O | Bonding; Reversed-phase chromatography | ||
| Soluble in H2O | Soluble in THF | ||
| GPC | |||
| Unionization | Bonding; Reversed-phase chromatography | ||
| Ionization | |||
| Silica; Normal-phase chromatography | |||
| Ion exchange chromatography | |||
| More than 2000 | Soluble in organic solvents | GPC | |
| Soluble in H2O | GFC | ||
| Ion exchange chromatography | |||
| Macroporous packing; Reversed-phase chromatography | |||
In addition to this, the packing of the column has different effects on the separation of substances, and we offer the main packing materials:
- Al2O3 matrix: stable to strong acids and bases;
- Polymer matrix: stable to strong acid and alkali, surface chemistry can be carried out according to the needs of different chromatography;
- Silica gel matrix: high mechanical strength, fast separation speed, and good reproducibility, required for strong alkali separation.
Fig.2 Process of sample isolation and purification. (CD BioGlyco)
Workflow
Our purification constitutes a rigorously multistage continuum, methodically architected to optimize both immaculate yield and compound restitution. Each step is carefully controlled to ensure the highest quality product is delivered to our clients.
- Initial Sample Assessment and Consultation
The process begins with a detailed consultation to understand your specific project requirements, including sample type, desired purity, and downstream application. This allows our specialists to tailor the optimal purification strategy, including selecting the appropriate column chemistry and gradient protocol.
- Sample Preparation and Loading
Crude, synthesized nucleic acid samples are prepared for injection. This may involve initial desalting to remove small-molecule impurities that can interfere with the HPLC process. Primed specimen thereafter hydrodynamically vectored into chromatographic apparatus, propagated through its propulsive dissolvent flux toward the quiescent adsorptive substrate.
- High-Resolution Chromatographic Separation
This is the core purification step. As the nucleic acid mixture passes through the HPLC column, molecules interact with the stationary phase based on their physicochemical properties. Using a precisely controlled gradient of solvents, our system separates the full-length target molecules from all impurities, including truncated sequences, unincorporated nucleotides, and other synthesis byproducts. The high-resolution separation allows for the isolation of incredibly pure fractions, even those differing by just a single nucleotide.
- Fraction Collection and Quality Control (QC)
Chromatographically liberated molecular cohorts; interrogated by photonic symbionts, then sequestered as discrete consortia. Each fraction is then subjected to rigorous quality control analysis, which includes spectrophotometric quantification and mass spectrometry to verify purity, concentration, and molecular mass. This comprehensive QC provides transparent, reliable data on the final product.
- Product Finishing and Delivery
The high-purity fractions are prepared for delivery, typically through lyophilization to a dry powder. The final product is provided with a detailed QC report, including a chromatogram and purity data, ready for immediate use in your critical downstream applications.
Publication Data
DOI.: 10.1016/j.tet.2023.133774
Journal: Tetrahedron
IF: 2.2
Published: 2024
Results: This investigation delineates an unprecedented RP-HPLC purification methodology for oligonucleotides, capitalizing on divergent retention kinetics between target sequences and recalcitrant shortmer contaminants. By substituting conventional acetic anhydride capping with a lipophilic phosphoramidite reagent during solid-phase synthesis, selective 5′-terminal modification of the target oligonucleotide was achieved. This derivatization markedly attenuated its hydrophobicity relative to unmodified failure sequences, thereby enabling single-step fractionation wherein solely the target eluted prematurely from the reversed-phase stationary phase, while impurities exhibited prolonged adsorption. The technique obviates intricate gradient elution protocols and proves particularly efficacious for cholesterol-conjugated oligonucleotides, furnishing an expedient substitute for established HPLC purification regimens that falter with structurally analogous contaminants.
Applications
- HPLC could be used for the separation and purification of molecules of different molecular weights.
- HPLC is used for the separation and purification of pharmaceutical intermediates.
- HPLC could be used to assist in the development of DNA and gene technology.
Advantages
- Our HPLC methodology provides unparalleled resolution, especially critical for therapeutic research applications.
- The high purity of our product directly translates to superior performance in downstream applications. Purified oligonucleotides and mRNA exhibit higher translational efficiency and minimal off-target effects, providing robust and reliable results.
- Our service scales seamlessly from research-level quantities to large-scale manufacturing, providing a consistent and reliable purification solution as your project progresses from discovery to commercialization.
Frequently Asked Questions
Associated Services
Our DNA and RNA purification provides nucleotide-level precision for applications demanding structural integrity—from CRISPR guide RNAs to ribozyme scaffolds. To harness this precision for functional complexity, we offer De Novo Glycan Display, a platform that engineers cell-surface glycosylation landscapes to direct biological behaviors:
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
CD BioGlyco is a company with extensive experience in DNA and RNA research. We have professional research equipment for the efficient isolation and purification of DNA and RNA for our clients, and our high-quality service has earned us a good reputation around the world.
Clients can contact our staff directly and we will reply promptly. If you are interested in our services, please feel free to contact us for more details.
Reference
- Ren, Q.; et al. Development of simple purification method for oligonucleotides synthesized using phosphoramidite for 5′-end modification as capping reagent. Tetrahedron. 2024, 150: 133774. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




